Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 3, 2026Future Medicinal Chemistry

VEGFR-2 as a druggable target: recent advances (2025) in the development of five-membered heterocyclic anticancer agents

View Full Paper
Ask AI
Bookmark
Share

Key result

Five-membered heterocyclic scaffolds emerge as promising VEGFR-2 inhibitors to overcome resistance and improve safety.

Design

Review

Authors

MKMohamed M. KhalifaCairo UniversityISIbtehal Nasser SalmanUniversity of KerbalaRJReyadh JassemAhl Al Bayt University

Discussion

Loading...

Member takes

Implication

Supports scaffold optimization for selective VEGFR-2 inhibition; leaves open clinical translation in resistant cancers.

Key Points

  • To review recent advances in the rational design, synthesis, and biological assessment of five-membered heterocyclic VEGFR-2 inhibitors aimed at overcoming resistance and toxicity.
  • Systematically analyzed recent progress in developing five-membered heterocyclic scaffolds, including thiadiazole, oxazole, thiazole, pyrrole, pyrazole, and imidazole derivatives.
  • Evaluated molecular hybridization strategies targeting hinge-binding regions, DFG motifs, and allosteric pockets, along with detailed structure-activity relationships.
  • Five-membered heterocyclic scaffolds offer adaptable structural frameworks for designing highly selective VEGFR-2 inhibitors with enhanced binding interactions.
  • Optimizing substituent variations on these heterocycles improves pharmacokinetics, safety margins, and potency against drug-resistant tumor pathways.

Structured PICO

I
Intervention
Five-membered heterocyclic scaffolds (thiadiazol, oxazole, thiazole, pyrrole, pyrazole, and imidazole-based inhibitors) as novel VEGFR-2 inhibitors

This review highlights recent advances in the design and synthesis of five-membered heterocyclic scaffolds as next-generation VEGFR-2 inhibitors to overcome limitations of first-generation drugs.

Cite This Study

Khalifa et al. (2026) conducted a review in Cancer. Five-membered heterocyclic scaffolds (VEGFR-2 inhibitors) was evaluated. Five-membered heterocyclic scaffolds represent promising novel VEGFR-2 inhibitors engineered to overcome resistance and improve safety compared to first-generation agents.

synapsesocial.com/papers/6a993600636c6408cfa7ebcbhttps://doi.org/10.1080/17568919.2026.2726194
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched one closely related paper. Consider it for comparative context:

  1. 1Discovery of new thiadiazole-based VEGFR-2 inhibitors: design, synthesis, cytotoxicity, and apoptosis induction2025 · 7 citations